KCM
UTHR icon

Kingdon Capital Management’s United Therapeutics UTHR Stock Holding History

Kingdon Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-35,600
Closed -$4.61M – 180
2014
Q4 		$4.61M Buy
+35,600
New +$4.59M 0.2% 109

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Kingdon Capital Management's UTHR Position: Q1 2015 in Review

Kingdon Capital Management sold out of United Therapeutics (UTHR) in Q1 2015, closing a stake of 35,600 shares — an estimated $4.61M sold.

Kingdon Capital Management first reported a position in UTHR in Q4 2014 and held it in 1 quarter. The position peaked at $4.61M in Q4 2014. 366 funds tracked by Wall St. Rank hold UTHR as of Q1 2015.

  • Kingdon Capital Management reported no remaining United Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Kingdon Capital Management sold 35,600 United Therapeutics shares in Q1 2015, an estimated $4.61M.
  • Kingdon Capital Management first reported a position in United Therapeutics in Q4 2014 and held it in 1 quarter.
  • Kingdon Capital Management's United Therapeutics position peaked at $4.61M in Q4 2014.
  • 366 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2015.

Based on Kingdon Capital Management's 13F filing for Q1 2015, filed 15 May 2015.